Piotr Lukasz Rutkowski
Istituto Oncologico Veneto · 1,516 works · 84,544 citations · h-index 111
Top works
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts
- Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
- Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
- Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma